//= $__courseRemotePath ?>
//= $videoEmbedCode ?>
In this CME activity Elias Jabbour, MD, provides his perspectives on key posters presented at the American Society of Hematology's 60th Annual Meeting & Exposition held in San Diego, California, on the treatment of patients with acute lymphoblastic leukemia (ALL). We invite you to learn more about the current and emerging standards of care, as well as safety and efficacy data from the select clinical trials, in patients with acute lymphoblastic leukemia.
Elias Jabbour, MD
Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
- CD19-positive ALL
- A bispecific T-cell engager antibody
- Antibody drug conjugate
- Low-intensity chemotherapy
- Philadelphia chromosome-negative ALL
- Minimal residual disease
- Veno-occlusive disease
- Allogeneic stem-cell transplantation
1.00 AMA PRA Category 1 Credit™.
||April 30, 2019
||April 29, 2020
Other Healthcare Providers
This activity is supported by educational funding provided by Amgen.
Enter your information to begin.
This activity is intended for hematologist-oncologists and other clinicians interested in the management of patients with acute lymphoblastic leukemia (ALL).